SureTrader SureTrader
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, otclad
Search This Board:
Last Post: 10/27/2016 10:07:08 PM - Followers: 182 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#11918   No big fish in this pond it has Axeman 10/27/16 10:07:08 PM
#11917   Be patient this will pay off just waiting stockscheers 10/27/16 10:06:10 PM
#11916   Converting like there's no tomorrow no-bid coming again Axeman 10/27/16 04:52:14 PM
#11915   Okie dokie good luck to us. My big Axeman 10/25/16 02:16:42 PM
#11914   Wake up! You said the same thing stoprun 10/25/16 02:15:13 PM
#11913   Wake up. Call Ben and do your research Axeman 10/25/16 02:03:23 PM
#11912   "Carnac The Magnificent", do you have access to stoprun 10/25/16 01:58:32 PM
#11911   FEB 2016. Even with good news it won't Axeman 10/25/16 01:21:42 PM
#11910   So still trying to get trials started but brando5 10/25/16 01:19:29 PM
#11909   There are no trials Ben has no money Axeman 10/25/16 01:16:41 PM
#11908   So market cap is below 1 million only brando5 10/25/16 01:15:23 PM
#11907   OS 815,662,347 as of 10-25-16 Axeman 10/25/16 01:08:33 PM
#11906   RCHA has a lot more under the hood. stockscheers 10/24/16 08:28:29 PM
#11905   I would say 90% of the dumping is Axeman 10/24/16 01:54:30 PM
#11904   How many of those 60M are real, or stoprun 10/24/16 01:47:34 PM
#11903   60 million on ask. Ben and his dilutive Axeman 10/24/16 11:37:42 AM
#11902   Go read the filings. There are a ton Axeman 10/23/16 10:13:06 AM
#11901   Link Please!!!!!!!!!!!!! stoprun 10/23/16 09:44:27 AM
#11900   You guys just don't get it. Unlimited amount Axeman 10/23/16 01:44:29 AM
#11899   Nice hit indeed. Still not sold. otclad 10/21/16 02:32:07 PM
#11898   Wow - nice milly slaps on 2s. RCHA rebounding!!! OTC Knight 10/21/16 12:38:33 PM
#11897   BIG TIME MOVE COMING HERE!! stockscheers 10/20/16 12:04:44 AM
#11896   Look at the past - Toxic convertibles are Axeman 10/19/16 12:50:15 PM
#11895   We need NEWS!! Go RCHA!! Rich540 10/19/16 07:17:08 AM
#11894   0003s coming here any day now!!! OTC Knight 10/18/16 07:55:49 PM
#11893   Last time RCHA upticked it was VERY THIN! PENNYMACHINE 10/18/16 12:53:39 PM
#11892   5 milly slap on 2s!!!! OTC Knight 10/18/16 11:24:51 AM
#11891   We know Litigation Settled through confidential process supervised PENNYMACHINE 10/18/16 11:01:23 AM
#11890   Listen..Ben's toxic deals have a strangle hold on Axeman 10/17/16 11:32:14 PM
#11889   I'm ready to see 0003s this week!!! OTC Knight 10/16/16 11:56:44 PM
#11888   Surely positive cash flow, Monday is gonna be stockscheers 10/16/16 09:57:43 PM
#11887   RCHA looks ready for rebound!!!! OTC Knight 10/14/16 09:38:09 AM
#11886   Toxic dumping. OS keeps growing. Axeman 10/13/16 03:43:52 PM
#11885   Wow - nice milly slaps on ask. Here OTC Knight 10/13/16 09:55:56 AM
#11884   .0001 buy point only with this toxic debacle. Axeman 10/13/16 01:54:55 AM
#11883   hmm i smell something cooking over here,,,might nibble stockscheers 10/11/16 10:06:07 PM
#11882   2s clearing slow and steady here!!! OTC Knight 10/11/16 07:11:43 PM
#11881   Ben has locked this down with toxic financing. Axeman 10/10/16 01:31:21 PM
#11880   Nice milly slaps on 2s!!! OTC Knight 10/10/16 12:02:17 PM
#11879   Calm before the storm here. Lets see the OTC Knight 10/07/16 02:24:33 PM
#11878   looking for 0.0003 to clear again today MGL_Trader 10/07/16 09:26:40 AM
#11877   GM RCHA MGL_Trader 10/07/16 09:09:31 AM
#11876   Why? Seems like impetus from pr has Ognib 10/06/16 10:29:57 PM
#11875   RCHA lots of buyers here i expect this TomWilkinsPHD 10/06/16 07:52:54 PM
#11874   Only 3M at .0003 so far, Wow PENNYMACHINE 10/06/16 02:12:05 PM
#11873   This one Ready? PENNYMACHINE 10/06/16 02:07:24 PM
#11872   It already started to ramp up. stockscheers 10/05/16 01:32:56 PM
#11871   LMAO! WARNED YA!!! onthegreen 10/04/16 08:46:04 PM
#11870   Not looking good. Appears Management is just otclad 10/04/16 03:48:11 PM
#11869   Hopeless. Long-vestor 10/03/16 09:37:24 AM